The FDA has approved Repatha ... NCT02624869) that evaluated the efficacy and safety of evolocumab 420mg subcutaneously once monthly in patients 10 to 17 years of age with HoFH.

Amgen announced the submission of an application to the Food and Drug Administration (FDA) seeking approval of a single-injection option for the monthly administration of the 420mg dose of Repatha ...

Amgen’s treatment, called Repatha, met its goals in a two-year trial on more than 27,000 patients with heart disease who were already taking a maximum dose of statins like Lipitor and yet still ...

In 2016, Amgen (AMGN) expects Repatha, a novel PCSK9 inhibitor drug, to continue to capture global market share in the atherosclerosis segment.

Shares of Amgen, Inc. (NASDAQ: AMGN ) fell 7 percent after the biotechnology company released data from its therapy called Repatha , which is used to lower the risk of heart attacks, strokes and ...

FDA approves new cholesterol-lowering drugs. Repatha and a similar drug approved last month by the FDA are known as PCSK9 inhibitors because they block a substance that hinders the liver’s ...

Amgen Inc.AMGN-1.86%decrease; red down pointing triangle on Friday reported widely anticipated data on its new cholesterol-lowering drug Repatha, showing it reduced the risk of deaths, heart ...

In March 2015, Amgen is preparing for the launch of Repatha, a new molecule that has demonstrated a remarkable ability to treat high cholesterol. Through a series of clinical trials, Amgen has proven ...

Amgen’s cholesterol drug Repatha proved effective at lowering the risk of heart attacks, strokes and death in patients with heart disease in a recent clinical trial, reports Reuters. When ...

The FDA approved Amgen’s cholesterol-lowering drug on Thursday, teeing up a rivalry with a similar treatment that was approved just weeks earlier.

Repatha costs $14,000 a year and insurers often won’t pay. It is given as a do-it-yourself shot using a pen-like device, to be taken every two weeks, or once a month.